NMNAT1
NMNAT1 (nicotinamide nucleotide adenylyltransferase 1) is a nuclear enzyme that catalyses a key step in NAD(+) biosynthesis, forming NAD(+) from nicotinamide mononucleotide and ATP. Also known as NMNAT, PNAT1 and LCA9, it is linked to neuronal protection and to Leber congenital amaurosis 9. Browse Assay Genie's current range of NMNAT1 research reagents below, or read on for the biology behind the target.
NMNAT1 catalyses the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. It can use the deamidated substrate nicotinic acid mononucleotide (NaMN) with the same efficiency, and can also use triazofurin monophosphate. The enzyme also runs the reverse reaction, the pyrophosphorolytic cleavage of NAD(+), preferring NAD(+) and NaAD as substrates and degrading NADH, NHD and NGD less effectively. It does not cleave the phosphorylated dinucleotides NADP(+), NADPH or NaADP(+).
Within the nucleus, NMNAT1 takes part in ATP synthesis together with PARP1, PARG and NUDT5. This nuclear ATP supply is required for energy-consuming chromatin remodelling. NMNAT1 also acts as a cofactor for glutamate and aspartate ADP-ribosylation, directing PARP1 catalytic activity to glutamate and aspartate residues on histones. It protects against axonal degeneration after mechanical or toxic insults. This protection does not correlate with cellular NAD(+) levels, although it may still require enzyme activity. NCBI Gene notes that its activity leads to activation of a nuclear deacetylase that functions in protecting damaged neurons.
The NMNAT1 gene encodes a member of the eukaryotic NMN adenylyltransferase family, one of several nicotinamide nucleotide adenylyltransferases, and the protein is specifically localised to the cell nucleus. Mutations in the gene have been associated with Leber congenital amaurosis 9, which gave rise to the LCA9 alias. Alternative splicing produces multiple transcript variants, and pseudogenes are found on chromosomes 1, 3, 4, 14 and 15. The mouse ortholog is Nmnat1.
NMNAT1 catalyses a key step in NAD(+) biosynthesis, using NMN or NaMN with ATP, making it central to studies of nucleotide metabolism.
NMNAT1 protects against axonal degeneration after mechanical or toxic insults, and its activity leads to activation of a nuclear deacetylase protecting damaged neurons.
With PARP1, PARG and NUDT5, NMNAT1 supports nuclear ATP synthesis needed for energy-consuming chromatin remodelling.
Mutations in the NMNAT1 gene are associated with Leber congenital amaurosis 9, making it a target in retinal degeneration research.
NMNAT1 forms NAD(+) from nicotinamide mononucleotide and ATP, and can also cleave NAD(+) by pyrophosphorolysis. In the nucleus it contributes to ATP synthesis with PARP1, PARG and NUDT5, supports PARP1-directed ADP-ribosylation of histones, and protects against axonal degeneration.
The HGNC name is nicotinamide nucleotide adenylyltransferase 1. Aliases and previous symbols include NMNAT, PNAT1 and LCA9. Earlier names include nicotinamide nucleotide adenylyltransferase and Leber congenital amaurosis 9. UniProt calls it nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1. Alternative splicing gives multiple transcript variants.
Mutations in the NMNAT1 gene have been associated with Leber congenital amaurosis 9. The mouse ortholog is Nmnat1. Researchers should check the datasheet of any product for its validated reactivity before use in a given species.
Other NAD(+) biosynthesis enzymes, nuclear ADP-ribosylation partners and neuroprotection-related targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9HAN9; product specifications from Assay Genie datasheets.